| Toggle Summary
|
Minerva Neurosciences' Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
|
View HTML
|
| Toggle Summary
|
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
Management to host conference call
|
View HTML
|
| Toggle Summary
|
Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
|
View HTML
|
